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demonstrated that smoking is associated with increased 
axSpA severity markers in a dose–response manner. Par-
ticular effort should be made to restrict smoking exposure 
early before accruing a significant number of pack-years.
Keywords Axial spondyloarthritis · Ankylosing 
spondylitis · Cigarette smoking · Disease activity · 
Functional impairment
Introduction
Axial spondyloarthritis (axSpA) is a chronic inflammatory 
disease involving the entheses. Musculoskeletal involve-
ment is predominantly axial (sacroiliitis, spondylitis) lead-
ing to inflammatory back pain, but can be also involve 
peripheral joints and tendons (arthritis, enthesitis, dacty-
litis). AxSpA can be further divided into ‘radiographic’ 
(ankylosing spondylitis, AS) and ‘non-radiographic’ (nr-
axSpA), depending on whether definitive structural changes 
are evident on plain radiographs of sacroiliac joints [1, 2]. 
Patients with nr-axSpA may display active inflammation on 
magnetic resonance imaging (MRI). Nr-axSpA may repre-
sent early AS but may also be a limited form that is symp-
tomatically similar but does not lead to structural changes. 
Since delineation of nr-axSpA and AS is artificial and unre-
liable, both forms have been suggested to be one disease 
[3].
Cigarette smoking appears to have an important role in 
axSpA. Studies have demonstrated that smoking is associ-
ated with incident AS [4] and earlier onset of axSpA [5]. 
Smokers with AS have increased disease activity, func-
tional impairment and reduced quality of life [6, 7]. The 
reasons for these associations are not well understood but 
may reflect increased inflammatory burden associated 
Abstract A history of ever-smoking appears to be associ-
ated with a more severe disease phenotype in axial spon-
dyloarthritis (axSpA). However, evidence is sparse for the 
effect of increased smoking exposure on disease outcomes 
or whether smoking reduction or cessation improves out-
comes. The aim of this study was to explore whether a 
dose–response relationship exists between pack-years and 
disease activity and functional impairment in axSpA. Con-
secutive patients meeting ASAS criteria for axial SpA were 
recruited from a spondyloarthritis service. The associations 
between pack-years of smoking and: (1) disease activity 
(BASDAI/ASDAS), (2) spinal pain, (3) functional impair-
ment (BASFI) and (4) inflammatory markers were explored 
using multivariable linear models, adjusted for age, gender 
and use of TNF inhibition (TNFi) therapy. Pack-years were 
categorised into four groups (<10, 11–20, 21–40, >40) and 
analysed with light smoking (<10) as reference. Two hun-
dred and thirty-eight axSpA patients were recruited: 76% 
were male, mean age 46.4 years (SD ± 13.7), and 33% 
were treated with TNFi. One hundred and twelve patients 
reported history of ever-smoking with median pack-year 
20 [IQR10-30]. Compared to light smokers, those with 
higher categories of smoking exposures had higher BAS-
DAI (21–40 pack-years, β = 1.6 (95% CI 0.28, 2.95); 
>40, β = 2.6 (0.54, 3.56)), higher BASFI (21–40, β = 2.1 
(0.42, 4.80); >40, β = 3.2 (0.76, 5.71)), and higher ASDAS 
(21–40, β = 0.82 (0.14, 1.51)). This cross-sectional study 
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with smoking or possibly confounding effects of socio-
economic class. However, previous studies exploring asso-
ciation between smoking and disease severity have utilised 
cross-sectional study designs, which limit causal inference. 
Exploring the dose–response relationship between smoking 
and disease severity may provide more evidence for causal 
relationship. Existing studies have mostly been in small 
cohorts with varying results and many methodological 
limitations [8–13]. The aims of this study were to test the 
hypothesis that pack-years of cumulative exposure to ciga-
rette smoking in ever-smokers are associated with disease 
activity and functional impairment in axSpA and to quan-
tify its effect size.
Method
Consecutive patients attending a tertiary referral spondy-
loarthritis service, in a UK hospital setting, were recruited 
between September 2010 and December 2015. Patients 
were included if they fulfilled the ASAS criteria for axial 
SpA [2].
Clinical data were collected during routine out-patient 
assessments. Patient characteristics were recorded includ-
ing: age, gender, body mass index (BMI). Smoking status 
was categorised as current smoker, ex-smoker and non-
smoker. For patients who have ever smoked (current and 
ex-smokers), total cumulative exposure was estimated with 
pack-years: one pack-year equals cigarettes per day multi-
plied by number of years smoked divided by 20. In addi-
tion, disease variables were recorded including: classifica-
tion as AS, symptom duration, duration since diagnosis, 
HLA-B27 status if available and extra-axial disease fea-
tures (peripheral joint involvement, psoriasis, uveitis and 
inflammatory bowel disease). HLA-B27 was not systemati-
cally tested in this real-life cohort and therefore was miss-
ing in a significant proportion. Current use of non-steroidal 
anti-inflammatory drugs (NSAIDs) and tumour necrosis 
factor inhibition (TNFi) was also recorded. Disease activity 
and functional status were assessed using numeric rating 
scale versions of the Bath AS Disease Activity Index (BAS-
DAI), spinal pain (spNRS) and Bath AS Functional Index 
(BASFI). Patient global was introduced into clinical prac-
tice after study commencement and was therefore incom-
plete with data missing at random. Blood samples were 
taken on the day of assessment, for analysis of erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). 
Ankylosing Spondylitis Disease Activity Score (ASDAS) 
was calculated using CRP for patients with complete data 
[14].
Statistical analyses were performed using Stata12. Com-
parison of patient and disease characteristics between the 
three smoking categories were performed using ANOVA 
for Gaussian, Kruskal–Wallis test (or Mann–Whitney U 
if two categories) for non-Gaussian and Chi-squared or 
Fisher’s exact test for categorical variables. Multivariable 
linear regression models were used to explore the asso-
ciation between each measure of disease activity (BAS-
DAI, ASDAS, spNRS, BASFI, CRP and ESR) in turn as 
the dependent variable, and non-/ever-smoking as the 
dichotomous independent variable, adjusted for age, gen-
der and use of TNFi. Symptom duration was not included 
as a covariate, given its collinearity with age. Due to their 
non-Gaussian distribution, ESR and CRP were log-trans-
formed prior to regression (ln(ESR), ln(CRP)). ASDAS 
was regressed using complete case analysis and again using 
multiple imputation for those with missing patient global 
scores. Multiple imputation was performed using multivari-
ate normal distribution with 30 imputed datasets. Variables 
used in the imputation model were those specified in the 
regression models, with BASDAI in addition as an aux-
iliary variable [15]. The aim of this study was to explore 
associations between smoking and disease activity. As 
patients with both AS and nr-axSpA can manifest similar 
levels of disease activity [3], these patients were grouped 
together in the analyses.
To explore the effect of pack-years on the above mark-
ers of disease severity, the same multivariable linear mod-
els were used, with pack-years as the independent variable 
categorised into four groups (<10, 11–20, 21–40 and >40 
pack-years) and analysed as dummy variables with <10 
pack-years as the reference. Categorisation was arbitrary to 
give similar groups sizes. Results were presented as coef-
ficients and 95% confidence intervals (95% CI). Residuals 
from each model were tested against normal distribution 
using Shapiro–Francia test.
This study received UK Research Ethics Committee 
approval (15/LO/1519).
Results
The study recruited 238 patients with established axSpA. 
The cohort was predominantly male (76%) with mean age 
of 46.4 years (SD ± 13.7), median symptom duration of 
17.1 years [inter-quartile rage (IQR) 8.4, 29.3] and median 
duration since diagnosis of 5.0 years [IQR 0.8, 14.8]. HLA-
B27 was measured in 61% of the cohort and of these 61% 
were positive. AS was present in 83%. Use of NSAIDs was 
reported by 163 (68%) patients, and 79 (33%) were treated 
with TNFi.
At the time of assessment, a history of ever-smok-
ing was reported by 112 (47%) patients with 78 (33%) 
reporting current smoking. Among ever-smokers, the 
median pack-year was 20 [IQR 10, 30]. The mean age of 
ex-smokers was older at 52 years, with similar ages of 
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current smokers at 45 years and non-smokers at 46 years. 
Similarly, symptom duration was longest in the ex-smoker 
group at 23 years. There were also more males (91%) in the 
ex-smoking group than other groups. The median BASDAI 
was 5.7 [IQR 3.3, 7.6] and BASFI 5.7 [3.3, 7.6]. ASDAS 
was available for 188 (79%) patients with mean of 2.7 
(SD ± 1.14). Patient demographics and disease character-
istics compared between smoking categories are shown in 
Table 1.
No significant differences were seen between smoking 
groups for duration since diagnosis. Proportion of AS was 
higher in current smokers compared with rest of the cohort 
(91 vs. 79%, P = 0.019).
Extra-axial features were similarly prevalent between 
the three smoking categories. However, the prevalence of 
uveitis was lower in current smokers compared to rest of 
the cohort (18 vs. 31%, P = 0.03).
Median disease severity measures were all higher in cur-
rent and ex-smokers than non-smokers, but there were no 
statistically significant differences between the three smok-
ing categories. Compared to non-smokers, ever-smokers 
had significantly higher BASDAI, ASDAS and BASFI, 
but not spNRS, ESR or CRP (data not shown). The use of 
TNFi and NSAIDs was similar between three groups.
In all multivariable models, no significant interactions 
were found between independent variables. NSAID-use 
and HLA-B27 were not included as covariates as they did 
not demonstrate significant association in, or improvement 
to, the models. In multivariable linear regression models, 
ever-smoking was independently associated with higher 
BASDAI (β = 0.91, 95% CI 0.26, 1.55), spNRS (β = 0.85, 
95% CI 0.11, 1.59) and BASFI (β = 0.82, 95% CI 0.10, 
1.53). Ever-smoking was also associated with ASDAS 
using complete case analysis (β = 0.70, 95% CI 0.39, 1.01) 
and multiply imputed data (β = 0.71, 95% CI 0.40, 1.01). 
However, ever-smoking was not associated with CRP 
(β = 2.68, 95% CI −1.85, 7.21) or ESR (β = 4.34, 95% CI 
−0.91, 9.58).
Multivariable linear models exploring associations with 
pack-year categories demonstrated significant dose-related 
increase for BASDAI, ASDAS and BASFI but not spNRS, 
CRP or ESR (Table 2). Compared to the <10 pack-year 
Table 1  Patient and disease characteristics of the cohort and for each smoking category
Data are presented in n (%), mean (SD), median [IQR] and comparison used Chi-squared/Fisher’s exact, ANOVA and Kruskal–Wallis tests, 
respectively
axSpA axial spondyloarthritis, ASDAS Ankylosing Spondylitis Disease Activity Score, BMI body mass index, IBD inflammatory bowel disease, 
TNFi TNF inhibition therapy, NSAID non-steroidal anti-inflammatory drugs
a  BMI complete data in 190; HLAB27 status known in 146; ASDAS in 188; CRP in 231; ESR in 230
b  Mann–Whitney U test
All Non-smokers Ex-smokers Current smokers P value
Number of patients 238 126 (52.9%) 34 (14.3%) 78 (32.8%)
Age 46.4 (13.8) 46.1 (14.2) 51.7 (12.1) 44.6 (13.2) 0.046
Male gender 180 (75.6%) 87 (69.1%) 31 (91.2%) 62 (79.5%) 0.018
BMIa 27.6 [25.1, 31.0] 27.4 [25.2, 30.5] 29.0 [25.8, 32.6] 27.6 [24.7, 31.0] 0.443
AS diagnosis 197 (82.8%) 99 (78.6%) 27 (79.4%) 71 (91.0%) 0.062
HLA-B27 statusa 89 (61.0%) 49 (59.8%) 14 (70.0%) 26 (59.1%) 0.670
Symptom duration (years) 16.5 [8.4, 28.4] 15.0 [6.4, 30.0] 23.1 [12.6, 33.1] 16.3 [8.8. 26.7] 0.033
Diagnosis duration (years) 5.0 [0.8, 14.8] 4.7 [0.8, 15.2] 4.0 [1.2, 14.8] 0.9 [5.4, 14.4] 0.802
Pack-years 0 [0, 15] 0 20 [10, 30] 15 [9, 30] 0.151b
BASDAI 5.7 [3.3, 7.6] 5.2 [3.0, 7.5] 6.0 [4.1, 8.2] 6.5 [3.6, 7.6] 0.132
Spinal pain 6.0 [3.0, 8.0] 5.0 [2.0, 8.0] 7.0 [3.0, 8.0] 7.0 [3.0, 8.0] 0.254
ASDASa 2.70 (1.14) 2.39 (1.16) 3.28 (1.08) 2.96 (0.98) 0.001
BASFI 5.7 [2.9, 7.6] 5.0 [2.3, 7.4] 6.9 [3.1, 8.1] 5.9 [3.2, 7.7] 0.116
CRP (mg/l)a 3 [1, 9] 3 [1, 8] 5 [2, 11] 5 [1, 11] 0.131
ESR (mm/hr) a 8 [5, 21] 8 [5, 19] 10 [6, 26] 10[5, 26] 0.123
Peripheral joint involvement 55 (23.6%) 35 (28.0%) 8 (23.5%) 12 (16.2%) 0.167
Psoriasis 39 (16.4%) 21 (16.70%) 6 (17.7%) 12 (15.4%) 0.949
Uveitis 64 (26.9%) 38 (30.2%) 12 (35.3%) 14 (18.0%) 0.079
IBD 22 (9.2%) 14 (11.1%) 3 (8.8%) 5 (6.4%) 0.576
TNFi 79 (33.2%) 39 (31.0%) 12 (35.3%) 28 (35.9%) 0.737
NSAID 163 (68.5%) 87 (69.1%) 20 (58.8%) 56 (71.8%) 0.390
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reference group, smokers with 11–20 pack-years did not 
have significantly higher BASDAI or BASFI. However, 
heavier smokers with 21–40 pack-years had scores 1.6 
higher for BASDAI and 2.1 higher for BASFI than the ref-
erence group. The group with >40 pack-year exposure had 
scores 2.6 and 3.2 higher than the reference group for BAS-
DAI and BASFI, respectively. Pack-years were also associ-
ated with ASDAS; however, this was not significant in the 
highest smoking category. Smokers with 21–40 pack-years 
had nearly one point higher ASDAS than the reference 
group. Residuals from all regression models were not sta-
tistically different from the normal distribution.
Discussion
This cross-sectional study of an axSpA cohort has demon-
strated that smoking is associated with increased disease 
activity and functional impairment. In axSpA participants 
reporting history of ever-smoking, increased cumulative 
smoking exposure was observed to have a clear independ-
ent and significant association with BASDAI and BASFI. 
This was irrespective of whether participants were current 
or ex-smokers. Compared to light smoking exposures (<10 
pack-years), those with higher pack-year smoking histories 
had increased BASDAI and BASFI. Ever-smokers with 
21–40 pack-year history had BASDAI and BASFI approxi-
mately two points higher than light smokers. Scores were 
highest in those with more than 40 pack-years of smoking.
A trend was also demonstrated for the more sensi-
tive index ASDAS. The loss of statistical significance for 
the heaviest pack-year category is likely due to the small 
size of this group. No significant associations were dem-
onstrated for ESR or CRP. The effect sizes increased with 
increasing pack-year categories; therefore, it may be that 
statistical power was insufficient. CRP and ESR are not 
specific markers of axSpA disease activity and may be 
influenced by other factors.
These findings are in agreement with three of the six 
existing studies of pack-years in AS [7, 8, 13]. Chen et al. 
[8] reported unadjusted correlation between pack-years 
and BASFI, but not BASDAI, ESR or CRP. An Iranian 
study found pack-years to be associated with BASDAI and 
of quality of life (QoL) but not BASMI in cohort of very 
light current smokers (median of 0.6 pack-years) [13]. The 
largest and most robust study found associations between 
categories of pack-years and all of their markers includ-
ing BASDAI, BASFI, pain numerical rating score and two 
measures of QoL [7].
The three remaining studies reported no associations 
between markers of disease severity and pack-years [11, 
12, 16]. There are several possible explanations for the 
inconsistent results. Firstly, it is important to consider 
confounders when studying smoking and disease activ-
ity. Some studies used simple correlation [8, 16] and oth-
ers used variable approaches when selecting covariates 
[12, 13]. Secondly, most studies recruited smaller cohorts 
with fewer (35–84 patients) entered into pack-year analysis 
[8, 11–13]. The larger studies were also not without limi-
tations: one was survey-based with 64% response rate to 
postal survey and no adjustment for TNFi [7] and the other 
explored association with BASFI alone with unadjusted 
correlation [16]. Our study is the first to quantify effect size 
of the association between pack-years and markers of dis-
ease activity using multi-adjusted analysis.
Our finding that only heavier smokers (>20 pack-years) 
had significantly higher disease activity was also observed 
by Mattey et al. [7] In their survey study of AS patients 
using a test for trend, BASDAI, BASFI, pain and two QoL 
measures were all associated with higher smoking exposure 
Table 2  Multivariable linear regression models of association between pack-year categories and measures of disease activity (adjusted for age, 
gender and use of TNFi)
Statistically significant values are represented in bold
Results are presented as β coefficient (95% confidence interval)
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath AS Func-
tional Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate
<10 pack-years n = 40 11–20 pack-years n = 34 21–40 pack-years n = 32 >40 pack-years n = 6
BASDAI Reference 0.55 (−0.55, 1.65) 1.62 (0.28, 2.95) 2.61 (0.42, 4.80)
ASDAS complete case analysis Reference 0.31 (−0.23, 0.84) 0.82 (0.14, 1.51) 0.54 (−0.53, 1.62)
ASDAS multiply imputed Reference 0.33 (−0.20, 0.86) 0.92 (0.25, 1.59) 0.88 (−17, 1.93)
Spinal pain Reference 0.54 (−0.77, 1.85) 1.34 (−0.25, 2.93) 1.40 (−1.21, 4.01)
BASFI Reference 0.95 (−0.29, 2.20) 2.05 (0.54, 3.56) 3.24 (0.76, 5.71)
CRP Reference 0.08 (−0.56, 0.72) 0.53 (−0.24, 1.30) 1.08 (−0.22, 2.37)
ESR Reference 0.27 (−0.26, 0.80) 0.28 (−0.38, 0.93) 0.71 (−0.33, 1.76)
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(>15 pack-years), but not for those with ≤15 pack-years. 
This is more likely as a result of statistical rather than bio-
logical effects.
In our axSpA cohort, those with a history of ever-smok-
ing had more severe disease than non-smoking participants. 
This was in agreement with previous studies [5, 7, 8, 11]. 
Ex-smokers were older and had longer symptom duration 
than current or non-smokers. This was also observed by 
Mattey et al. and may be that smoking tends to start at a 
younger age.
AS was more prevalent in current than non-current 
smokers. This could not be explained by age or gender 
(factors associated with radiographic progression); current 
smokers were younger with shorter disease and symptom 
duration and did not have more males than other groups. 
Other studies have reported greater radiographic progres-
sion in AS smokers [9, 10, 12].
It was also interesting to observe that uveitis was 
reported less frequently in current smokers, compared to 
ex-/non-smokers. Cigarette smoking is a recognised risk 
factor for uveitis in the general population [17]. However, 
development of the extra-articular disease manifestation 
may trigger smoking cessation behaviour. This finding was 
also reported in a larger Scottish cohort, where the authors 
hypothesised that cigarette smoke may be an irritant in 
those with uveitis leading to increased rates of cessation, 
or that the effect of uveitis on quality of life may have a 
particular impact on health behaviour [18]. This may also 
be one of many risk factor paradoxes due to collider-strati-
fication bias described in detail in 19.
The disparity between symptom and disease duration 
in this cohort suggests a prolonged delay to referral to the 
SpA service for diagnosis. This reflects the ongoing need 
to raise awareness of axSpA in primary care. Continuous 
NSAIDs was not promoted at this spondyloarthritis service 
given side effects and uncertain benefit [20]. Patients in this 
cohort generally took NSAIDs on-demand, and NSAID 
index was therefore not used.
There were several limitations to this study. The cross-
sectional design limits ability to infer causality between 
smoking and disease severity. However, the clear dose–
response relationship provides some support for smoking 
causing more severe disease phenotype in axSpA. Stud-
ies of smoking status are always subject to social desir-
ability bias. It is possible that patients are misclassified 
by self-reported smoking status. This is especially true 
for ex- and current-smoking groups and is one reason that 
they were analysed together under ever-smokers. Future 
studies should set more stringent definitions of ex-smok-
ing. This will allow separately analysis of dose–response 
relationship in ex- and current smokers. The categorisa-
tion of pack-years left only a small subgroup with heaviest 
(>40) pack-year exposure. Importantly, due to limited data 
collection, no adjustment was made for socioeconomic 
class in this study, although pack-years have been associ-
ated with disease activity independent of socioeconomic 
class [7, 18].
In conclusion, this study found that cigarette smoking 
was associated with increased axSpA severity in a clear 
dose–response manner. This dose–response relationship 
persists even in those who have quit smoking. Therefore, 
smoking cessation may be more beneficial if implemented 
before accruing a large number of pack-years. It is impor-
tant for clinicians to help patients with smoking cessation 
and smoking reduction as early as possible.
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